On February 28, 2013 at 9 AM EST / 3 PM CET Visiopharm will host a webinar titled “Progression Markers in Non-Muscle Invasive Bladder Cancer” presented by Dr. Niels Fristrup from Aarhus University Hospital, Denmark. This webinar coordinates with Visiopharm’s Cancer Research APPs for Bladder Cancer. Our current six Bladder Cancer APPs include:
- Bladder, Annexin 10, Biomarker Expression
- Bladder, MCM7, Biomarker expression
- Bladder, UBE2C, Biomarker expression
- Bladder, TRIM29, Biomarker expression
- Bladder, Survivin, Biomarker expression
- Bladder, CyclinD1, Biomarker expression
Transcripts from the four genes encoding cyclin D1, MCM7, TRIM29, and UBE2C have previously been included in gene expression signatures for outcome prediction in stage Ta/T1 urothelial carcinomas. Here, we investigated the prognostic value of the protein expressions in patients with stage Ta/T1 urothelial carcinomas. We used four different tissue microarrays with a total of 859 Ta/T1 urothelial carcinomas from Danish, Swedish, Spanish, and Taiwanese patient cohorts with long-term follow-up. Protein expression was measured by immunohistochemistry, and antibody specificity was validated by Western blotting.We found the expression of cyclin D1, MCM7, TRIM29, and UBE2C to be significantly associated with progression to muscle-invasive bladder cancer (log-rank test; p<0.001) in the Danish training cohort (n=283). Multivariate Cox regression analysis identified cyclin D1 (p=0.003), TRIM29 (p=0.001), and UBE2C (p<0.001) as independent prognostic markers. The prognostic value of the four proteins was validated in a joint validation cohort from Sweden, Spain, and Taiwan (n=576). We applied computer-assisted image analysis of the prognostic markers and produced results comparable to those obtained by manual scoring. Finally, a four-protein maximum-likelihood classifier was trained on the Danish training cohort; and applied to the validation cohort. The four protein markers may help optimize treatment of patients with Ta/T1 bladder cancer. Additional prospective studies are needed for further validation of their clinical relevance.
About our Speaker
Niels Fristrup was educated as a medical doctor from the University of Aarhus in 2010. His research started in 2008, primarily concerning prognostic protein markers in non-muscle invasive bladder cancer, now also focusing on predictive markers of Bacillus Calmette Guérin (BCG) treatment response. In his research Niels works to correlate advanced molecular analyses of cancer tissues from patients suffering from bladder cancer with extensive long-term follow-up of large patient cohorts. The goal is to create new, precise ways of identifying the aggressiveness of the cancers as early as possible, or the responsiveness towards BCG immunotherapy. This resarch could potentially lead to a more precise prognostication, again leading towards personalized medicine; the right treatment for each patient. Niels publication list encompasses 10 peer-reviewed articles in renowned journals as The American Journal of Pathology, Oncogene, and Cancer Research.